Bryan Egner

Title: Innovations of Bryan Egner in Gastrointestinal Treatment

Introduction

Bryan Egner is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of gastrointestinal disorders through his innovative research and development of novel compounds.

Latest Patents

Bryan Egner holds a patent for "Imidazole variants as modulators of GABA receptor for the treatment of GI disorders." This invention relates to novel compounds that exhibit a positive allosteric GABA receptor (GDR) modulator effect. The patent outlines methods for the preparation of these compounds and their use, optionally in combination with a GABAB agonist, to inhibit transient lower esophageal sphincter relaxations. This innovation aims to treat gastroesophageal reflux disease, functional gastrointestinal disorders, and irritable bowel syndrome (IBS). He has 1 patent to his name.

Career Highlights

Bryan Egner is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work focuses on developing therapeutic solutions for gastrointestinal issues, showcasing his commitment to improving patient outcomes.

Collaborations

Throughout his career, Bryan has collaborated with esteemed colleagues such as Udo Bauer and Wayne Brailsford. These partnerships have enhanced his research and contributed to the advancement of innovative treatments in the field.

Conclusion

Bryan Egner's contributions to the treatment of gastrointestinal disorders through his patented innovations highlight his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for new therapeutic approaches that can improve the quality of life for many patients.